Scores of Uruguayan travelers flocked the land crossings into Argentina as they waited to reach their destination for the entire week, probably to capitalize on a favorable currency exchange rate.
A 39-year-old patient in the Brazilian city of São Paulo has been determined to arguably be the first in the region with the Omicron XE variant of coronavirus.
Even after Uruguay's national Government has decreed the end of the sanitary restrictions stemming from the COVID-19 pandemic, the City Hall of Montevideo Tuesday urged the population to keep wearing facemasks “in buses, cabs, and other means of passenger transport.”
As cases of COVID-19 worldwide are waning down and more so are the disease's deadly effects, scientists worldwide are beginning to harbor new concerns over the appearance and spread of the so-called recombinant lineages of the SARS-CoV-2 Omicron variant.
According to a study released Tuesday by Brazil's Oswaldo Cruz Foundation (Fiocruz), patients who have taken the two-shot scheme of CoronaVac's drug would be better off if they receive a booster injection of the Pfizer vaccine.
The latest travel advice on Argentina from the Foreign Office points out that in 2019, (the last normal year), 126,548 British nationals visited Argentina in 2019 and most visits are trouble-free.
As a part of its zero-tolerance for covid-19 cases, the Government of China has been separating children from their parents to handle the recent outbreak in Shanghai.
Uruguay's President Luis Lacalle Pou Monday announced he would be lifting all sanitary restrictions in place in his country following a meeting with Health Minister and other aides.
The Government of Argentina has decreed a return to the prepandemic status regarding border controls. Travelers will have now the same requirements as before March 2020, Interior Minister Wado de Pedro and Migrations Director Florencia Carignano announced.
COVID-19 vaccines used in Brazil are effective to achieve protection from SARS-Cov-2 even for people who have previously had the disease, according to a study published this week in The Lancet by scientists from the Vigivac project at the Oswaldo Cruz Foundation (Fiocruz).